Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway?

Journal of Virology

Volumn 75, Issue 12, 2001, Pages 5443-5447

  Dix, Brett R ^a,b   Edwards, Sara J ^b   Braithwaite, Antony W ^b  

^a CURTIN UNIVERSITY   (Australia)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADENOVIRUS; CELL CYCLE; GENE TARGETING; GENE THERAPY; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TUMOR SUPPRESSOR GENE; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1B PROTEINS; HUMANS; MUTATION; NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035015925     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.12.5443-5447.2001     Document Type: Short Survey

References (63)

1. Babiss, L. E., and H. S. Ginsberg. 1984. Adenovirus type 5 early region 1b gene product is required for efficient shutoff of host protein synthesis. J. Virol. 50:202-212.
2. Barker, D. D., and A. J. Berk. 1987. Adenovirus proteins from both E1b reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156:107-121.
3. ARF links the tumour suppressors Rb and p53. Nature 395:124-125.
4. Bischoff, J. R., D. H. Kirn, A. Williams, C. Heise, S. Horn, M. Muna, L. Ng, J. A. Nye, A. Sampson-Johannes, A. Fattaey, and F. McCormick. 1996. An adenovirus mutant that replicates selectively in p53-deficient human tumour cells. Science 274:373-376.
5. Braithwaite, A., C. Nelson, A. Skulimowski, J. McGovern, D. Pigott, and J. Jenkins. 1990. Transactivation of the p53 oncogene by E1a gene products. Virology 177:595-605.
6. Braithwaite, A. W., B. F. Cheetham, P. Li, C. R. Parish, L. K. Waldron-Stevens, and A. J. D. Bellett. 1983. Adenovirus-induced alterations of the cell growth cycle: a requirement for expression of E1A but not of E1B. J. Virol. 45:192-199.
7. Braithwaite, A. W., J. D. Murray, and A. J. D. Bellett. 1981. Alterations to controls of cellular DNA synthesis by adenovirus infection. J. Virol. 39:331-340.
8. Cathomen, T., and M. D. Weitzman. 2000. A functional complex of adenovirus proteins E1B-55kDa and E4orf6 is necessary to modulate the expression level of p53 but not its transcriptional activity. J. Virol. 74:11407-11412.
9. Chiou, S.-K., C.-C. Tseng, L. Rao, and E. White. 1994. Functional complementation of the adenovirus E1B 19-kilodalton protein with Bcl-2 in the inhibition of apoptosis in infected cells. J. Virol. 68:6553-6566.
10. Dix, B. R., S. J. O'Carroll, C. J. Myers, S. J. Edwards, and A. W. Braithwaite. 2000. Efficient induction of cell death by adenoviruses requires binding of E1B55k and p53. Cancer Res. 60:2666-2672.
11. El-Deiry, W., T. Tokino, V. Velculescu, D. Levy, R. Parsons, J. Trent, D. Lin, E. Mercer, K. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumour suppression. Cell 75:817-825.
12. Goodrum, F. D., and D. A. Ornelles. 1997. The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. J. Virol. 71:548-561.
13. Goodrum, F. D., and D. A. Ornelles. 1998. p53 status does not determine outcome of E1b 55-kilodalton mutant adenovirus lytic infection. J. Virol. 72:9479-9490.
14. Grand, R., M. Grant, and P. Gallimore. 1994. Enhanced expression of p53 in human cells infected with mutant adenoviruses. Virology 203:229-240.
15. Grand, R. J., D. Owen, S. M. Rookes, and P. H. Gallimore. 1996. Control of p53 expression by adenovirus 12 early region 1A and early region 1B 54K proteins. Virology 218:23-34.
16. Hale, T. K., and A. W. Braithwaite. 1999. The adenovirus oncoprotein E1a stimulates binding of transcription factor ETF to transcriptionally activate the p53 gene. J. Biol. Chem. 274:23777-23786.
17. Hall, A. R., B. R. Dix, S. J. O'Carroll, and A. W. Braithwaite. 1998. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat. Med. 4:1068-1072.
18. Hansen, R., R. Reddel, and A. Braithwaite. 1995. The transforming oncoproteins determine the mechanism by which p53 suppresses cell transformation: pRb-mediated growth arrest or apoptosis. Oncogene 11:2535-2545.
19. Harada, J. N., and A. J. Berk. 1999. p53-independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J. Virol. 73:5333-5344.
20. Harper, W., G. Adami, N. Wei, K. Keyomarsi, and S. Elledge. 1993. The p21 CDK-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816.
21. Hay, J. G., N. Shapiro, H. Sauthoff, S. Heitner, W. Phupakdi, and W. N. Rom. 1999. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene. Hum. Gene Ther. 10:579-590.
22. Heise, C., M. Lemmon, and D. Kirn. 2000. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. Clin. Cancer Res. 6:4908-4914.
23. Heise, C., A. Sampson-Johannes, A. Williams, F. McCormick, D. D. Von Hoff, and D. H. Kirn. 1997. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3:639-645.
24. Heise, C. C., A. Williams, J. Olesch, and D. H. Kirn. 1999. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther. 6:499-504.
25. Heise, C. C., A. M. Williams, S. Xue, M. Propst, and D. H. Kirn. 1999. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res. 59:2623-2628.
26. Hodge, L. D., and M. D. Scharff. 1969. Effect of adenovirus on host cell DNA synthesis in synchronized cells. Virology 37:554-564.
27. Horwitz, M. S. 1971. Intermediates in the synthesis of type 2 adenovirus deoxyribonucleic acid. J. Virol. 8:675-683.
28. Hutchin, M. E., R. J. Pickles, and W. G. Yarbrough. 2000. Efficiency of adenovirus-mediated gene transfer to oropharyngeal epithelial cells correlates with cellular differentiation and human coxsackie and adenovirus receptor expression. Hum. Gene Ther. 11:2365-2375.
29. Hutton, F. G., A. S. Turnell, P. H. Gallimore, and R. J. Grand. 2000. Consequences of disruption of the interaction between p53 and the larger adenovirus early region 1B protein in adenovirus E1 transformed human cells. Oncogene 19:452-462.
30. Kao, C. C., P. Yew, and A. J. Berk. 1990. Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1b 55kDa protein. Virology 179:806-814.
31. Khuri, F. R., J. Nemunaitis, I. Ganly, J. Arseneau, I. F. Tannock, L. Romel, M. Gore, J. Ironside, R. H. MacDougall, C. Heise, B. Randlev, A. M. Gillenwater, P. Bruso, S. B. Kaye, W. K. Hong, and D. H. Kirn. 2000. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6:879-885.
32. Kirn, D., T. Hermiston, and F. McCormick. 1998. ONYX-015: clinical data are encouraging. Nat. Med. 4:1341-1342.
33. Lee, H., J. Kim, B. Lee, J. W. Chang, J. Ahn, J. O. Park, J. Choi, C. O. Yun, B. S. Kim, and J. H. Kim. 2000. Oncolytic virus potential of E1b 55kDa-deleted YKL-1 recombinant adenovirus: correlation with p53 functional status. Int. J. Cancer 88:454-463.
34. Marcellus, R. C., J. N. Lavoie, D. Boivin, G. C. Shore, G. Ketner, and P. E. Branton. 1998. The early region 4 orf4 protein of human adenovirus type 5 induces p53-independent cell death by apoptosis. J. Virol. 72:7144-7153.
35. McCarthy, S. A., H. S. Symonds, and T. Van Dyke. 1994. Regulation of apoptosis in transgenic mice by simian virus 40 T antigen-mediated inactivation of p53. Proc. Natl. Acad. Sci. USA 91:3979-3983.
36. Mittnacht, S. 1998. Control of pRB phosphorylation. Curr. Opin. Genet. Dev. 8:21-27.
37. Momand, J., G. Zambetti, D. Olson, D. George, and A. Levine. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245.
38. Mori, T., H. Arakawa, T. Tokino, K. Mineura, and Y. Nakamura. 1999. Significant increase of adenovirus infectivity in glioma cell lines by extracellular domain of hCAR. Oncol. Res. 11:513-521.
39. Nemunaitis, J., I. Ganly, F. Khuri, J. Arseneau, J. Kuhn, T. McCarty, S. Landers, P. Maples, L. Romel, B. Randlev, T. Reid, S. Kaye, and D. Kirn. 2000. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 60:6359-6366.
40. Nevins, J. R. 1994. Cell cycle targets of the DNA tumor viruses. Curr. Opin. Genet. Dev. 4:130-134.
41. Pilder, S., M. Moore, J. Logan, and T. Shenk. 1986. The adenovirus E1B-58K transforming polypeptide modulates transport or cytoplasmic stabilization of viral host cell mRNAs. Mol. Cell. Biochem. 6:470-476.
42. ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723.
43. Rao, L., M. Debbas, P. Sabbatini, D. Hockenbery, S. Korsmeyer, and E. White. 1992. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19kDa and Bcl-2 proteins. Proc. Natl. Acad. Sci. USA 89:7742-7746.
44. Ridgway, P. J., A. R. Hall, C. J. Myers, and A. W. Braithwaite. 1997. p53/E1b58kDa complex regulates adenovirus replication. Virology 237:404-413.
45. ARF in tumor cells facilitates replication of the adenovirus mutant dl 1520 (ONYX-015). Nat. Med. 6:1128-1133.
46. Rogulski, K. R., S. O. Freytag, K. Zhang, J. D. Gilbert, D. L. Paielli, J. H. Kim, C. C. Heise, and D. H. Kirn. 2000. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res. 60:1193-1196.
47. Rothmann, T., A. Hengstermann, N. J. Whitaker, M. Scheffner, and H. zur Hausen. 1998. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. 72:9470-9478.
48. Sarnow, P., P. Hearing, C. W. Anderson, D. N. Halbert, T. Shenk, and A. J. Levine. 1984. Adenovirus early region 1B 58,000-dalton tumor antigen is physically associated with an early region 4 25,000-dalton protein in productively infected cells. J. Virol. 49:692-700.
49. Sarnow, P., Y. S. Ho, J. Williams, and A. J. Levine. 1982. Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kD cellular protein in transformed cells. Cell 28: 387-394.
50. Shimojo, H., and T. Yamashita. 1968. Induction of DNA synthesis by adenoviruses in contact-inhibited hamster cells. Virology 36:422-433.
51. Stabel, S., P. Argos, and L. Philipson. 1985. The release of growth arrest by microinjection of adenovirus E1A DNA. EMBO J. 4:2329-2336.
52. Steegenga, W. T., N. Riteco, and J. L. Bos. 1999. Infectivity and expression of the early adenovirus proteins are important regulators of wild-type and DeltaE1B adenovirus replication in human cells. Oncogene 18:5032-5043.
53. Steegenga, W. T., N. Riteco, A. G. Jochemsen, F. J. Fallaux, and J. L. Bos. 1998. The large E1B protein together with the E4ORF6 protein target p53 for active degradation in adenovirus infected cells. Oncogene 16:349-357.
54. ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17:5001-5014.
55. Tomko, R. P., R. Xu, and L. Philipson. 1997. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. USA 94:3352-3356.
56. Turnell, A. S., R. J. A. Grand, and P. H. Gallimore. 1999. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status. J. Virol. 73:2074-2083.
57. Vollmer, C. M., A. Ribas, L. H. Butterfield, V. B. Dissette, K. J. Andrews, F. C. Eilber, L. D. Montejo, A. Y. Chen, B. Hu, J. A. Glaspy, W. H. McBride, and J. S. Economou. 1999. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Res. 59:4369-4374.
58. Vousden, K. H., B. Vojtesek, C. Fisher, and D. Lane. 1993. HPV-16 E7 or adenovirus E1A can overcome the growth arrest of cells immortalized with a temperature-sensitive p53. Oncogene 8:1697-1702.
59. Weber, J. D., L. J. Taylor, M. F. Roussel, C. J. Sherr, and D. Bar-Sagi. 1999. Nucleolar ARF sequesters Mdm2 and activates p53. Nat. Cell Biol. 1:20-26.
60. Whyte, P., K. J. Buchkovich, J. M. Horowitz, S. H. Friend, M. Raybuck, R. A. Weinberg, and E. Harlow. 1988. Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 334:124-129.
61. Wildner, O., and J. C. Morris. 2000. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity. Cancer Res. 60:4167-4174.
62. You, L., C. T. Yang, and D. M. Jablons. 2000. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res. 60:1009-1013.
63. Younghusband, H. B., C. Tyndall, and A. J. Bellett. 1979. Replication and interaction of virus DNA and cellular DNA in mouse cells infected by a human adenovirus. J Gen. Virol. 45:455-467.